Azathioprine & Allopurinol in Inflammatory Bowel Disease Patients

Inflammatory Bowel Disease Clinical Trial

Official title:

Dose-effect Relationship Between Allopurinol, Azathioprine and 6-thioguanine Nucleotide Levels (6-TGN) in Inflammatory Bowel Disease Patients.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00849368
• Other study ID #: PHA-08-AZA/ALLO-01
• Status: Completed
• Phase: Phase 1
• First received: September 2, 2008
• Last updated: February 6, 2012
• Start date: January 2009
• Est. completion date: September 2011

Study information

• Verified date: February 2012
• Source: University of Zurich
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Swissmedic
• Study type: Interventional

Clinical Trial Summary

Main Study Objectives:

The study is conducted to

• evaluate the minimal allopurinol and azathioprine doses that, in combination, produce therapeutic 6-TGN levels

• evaluate the safety and tolerability of the different allopurinol/azathioprine dose levels

• assess if concomitant allopurinol affects TPMT activity

• assess the clinical efficacy of concomitant allopurinol-azathioprine therapy in the included patients

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: September 2011
• Est. primary completion date: September 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion criteria:

• Able and willing to give written informed consent before any trial-specific procedures are performed

• Signed informed consent form

• Age 18 to 65 years at study entry

• Body Mass Index 18 - 30 kg/m2

• Confirmed diagnosis of either CROHN`s disease or ulcerative colitis prior to study enrollment by combinations of clinical, endoscopic and histologic criteria generally accepted for CD and UC

• Normal TPMT activity > 30 nmol MTG/gHb x h

• Insufficient disease control despite adequate therapy with corticosteroids and/or salicylic acid derivatives, and/or two or more episodes with steroid-requiring disease activity per year, and/or recurrence of disease activity at steroid doses below 15 mg prednisone equivalent, and/or recurrence within 6 weeks after steroid withdrawal.

Exclusion criteria:

• Subjects with confirmed or suspected hypersensitivity towards the study medication

• Contemporaneous participation in any other study

• Females only: pregnancy

• Females only: breast-feeding

• Prior thiopurine therapy

• Current and previous immunosuppressive therapy except corticosteroids (e.g. methotrexate, cyclosporine, mycophenolate mofetil, tacrolimus, infliximab or other TNF-alpha blocker therapy) within 3 months before the first drug intake

• Subjects with any clinically relevant comorbidity beyond the diagnosis of CROHN`s disease or ulcerative colitis (as based on extensive medical history, physical examination, vital signs, routine laboratory screen and 12-lead ECG)

• Haemoglobin < 12 g/dl at the screening examination

• Leucocytes < 3 x 10E3/µl at the screening examination

• Lymphocytes < 1.5 x 10E3/µl at the screening examination

• Thrombocytes < 140 x 10E3/µl at the screening examination

• Renal disease (creatinine clearance < 60 ml/min, assessed with MDRD formula), history of serious renal disease

• Liver disease (GGT, alkaline phosphatase, ALAT, ASAT > 2 times the upper limit of normal reference, known or suspected liver cirrhosis)

• Known or suspected malignancies of any kind

• Known or suspected active infections, serious infections in the preceding 3 months

• Active, acute or chronic, or history of, prior hepatitis B infection confirmed by a positive hepatitis B serology (positive HBsAg, Anti-HBc). Patients with a positive hepatitis C screening test (positive anti-HCV). Patients with a positive HIV testing (positive HIV 1 / 2 antibody tests)

• Active varicella zoster infection (chickenpox, shingles)

• Known or suspected symptomatic bowel stenoses or strictures, and patients who had a small bowel resection

• Subjects who are known or suspected not to be capable of understanding and evaluating the information that is given to them as part of the formal information policy (informed consent), in particular regarding the risks and discomfort to which they will be exposed

• Subjects who are known or suspected not to comply with the study directives and / or known or suspected not to be reliable or trustworthy

• Subjects who are not willing to comply with the instructions and duties concerning the subject insurance

• Women of childbearing age and potential who are not willing or capable to use acceptable methods of contraception (oral contraceptives, condoms, diaphragms, intrauterine devices) during the entire study and for up to three months after the end-of-study evaluation.

• Male patients who do not use acceptable barrier methods of contraception (condoms) during the entire course of the study and up to three months after the end-of-study evaluation

Study Design

Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Inflammatory Bowel Disease
• Inflammatory Bowel Diseases
• Intestinal Diseases

Intervention

Drug:
• Azathioprine / Allopurinol
Both drugs are applied orally. A pre-specified dose escalation regimen will be chosen. Azathioprine: Imurek (R) 50 mg and 25 mg tablets Allopurinol: Mephanol (R) 100 mg tablets

Locations

Country	Name	City	State
Switzerland	Division of Clinical Pharmacology and Toxicology, University Hospital Zurich	Zurich

Sponsors (1)

Lead Sponsor	Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics: Quantification of trough concentrations of 6-TGN and 6-MMPN in erythrocytes using HPLC at each dose level.		three times per cycle	No
Secondary	Dose escalation: Assessment of the percentage of patients who are in the desired therapeutic range on day 23-25 and on day 26-28 of each dose level.		once per cycle	Yes
Secondary	Efficacy: Change in disease activity score in relationship to the dose level attained.		once per cycle	No
Secondary	TPMT activity assessment		once per cycle	No
Secondary	Safety and Tolerability: Medical history, adverse events and well-being; laboratory screen, physical examination, vital functions: blood pressure, heart rate, body temperature		screening, up to three times per cycle, follow-up	Yes